Abstract
Levofloxacin is a broad-spectrum, rapid-acting bactericidal agent that exhibits concentration-dependent killing activity as well as a postantibiotic effect. Its activity includes enteric Gram-negative bacilli, Acinetobacter spp., Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus and most species of streptococci, including Streptococcus pneumoniae. With increasing age, there is a natural decline in renal function by approximately 1 ml/min/year after the age of 30 years, or an average decrease in creatinine clearance of 40% by the age of 80 years. This decline in renal function can have a significant impact on antibiotics that are predominantly eliminated from the body via the kidneys, such as levofloxacin. The favorable pharmacodynamic, safety and efficacy profiles, in addition to in vitro activity versus the usual respiratory pathogens, make levofloxacin among the first-line agents for the management of pneumonia, and an option for other respiratory bacterial infections in which more resistant organisms are a consideration, such as in the elderly population.